ScreenerHero

VREO Vireo Growth Inc.

CNQ · CA · Healthcare · Drug Manufacturers - Specialty & Generic · vireogrowth.com
6.628USD9.450 CAD · CNQ-2.07%Mkt Cap: 387.49M USDP/E: —

Vireo Growth Inc. operates as a cannabis company that cultivates, manufactures, processes, and distributes medical and adult-use cannabis products in Maryland, Minnesota, Missouri, Nevada, New York, and Utah. It sells ca…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all Drug Manufacturers - Specialty & Generic
MRK
Merck KGaA
$71.89BUSDP/E 28.1
TAK
Takeda Pharmaceutical Company Limited
$68.47BUSDP/E 306.1
GALD
Galderma Group AG
$53.24BUSDP/E 66.0
TEVA
Teva Pharmaceutical Industries Limited
$51.92BUSDP/E 103.5
SDZ
Sandoz Group AG
$43.66BUSDP/E 72.3
HLN
Haleon plc
$40.25BUSDP/E 18.7
ZTS
Zoetis Inc.
$34.06BUSDP/E 14.3
HLN
Haleon plc
$40.03BUSDP/E 19.2
UTHR
United Therapeutics Corporation
$25.18BUSDP/E 22.3
VTRS
Viatris Inc.
$23.87BUSD
NBIX
Neurocrine Biosciences, Inc.
$16.94BUSDP/E 24.8
SOBI
Swedish Orphan Biovitrum AB (publ)
$16.42BUSDP/E 25.0
IPN
Ipsen S.A.
$15.16BUSDP/E 27.0
ELAN
Elanco Animal Health Incorporated
$13.39BUSD
RDY
Dr. Reddy's Laboratories Limited
$12.29BUSDP/E 40.9
HLUN-B
H. Lundbeck A/S
$8.71BUSDP/E 14.5
HLUN-A
H. Lundbeck A/S
$8.54BUSDP/E 14.2
KRK
Krka, d. d.
$8.50BUSDP/E 19.2
ALKS
Alkermes plc
$7.90BUSD
KNSA
Kiniksa Pharmaceuticals International, plc
$7.57BUSDP/E 73.0
Institutional holders2 on file

Key Statistics

Company
Market Cap387.49M USD
Enterprise Value646.56M USD
Revenue (TTM)430.77M USD
Gross Profit127.10M USD
Net Income (TTM)-68.11M USD
Revenue/Share11.44 USD
Last Price6.628 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees520
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA92767B2049
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA15.94
EV/Revenue1.50
P/S1.28
P/B0.70
EPS (TTM)-2.35 USD
EPS (Forward)—
52W Range
5.9624% of range22.09
52W High22.09 USD
52W Low5.962 USD
Profitability
Gross Margin47.29%
Oper. Margin6.63%
EBITDA Margin13.43%
Profit Margin-25.34%
ROE-22.16%
ROA-8.34%
ROIC2.00%
ROCE1.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF3.71M USD
CapEx (TTM)29.82M USD
FCF Margin-51.91%
FCF Yield-57.71%
Net Debt429.50M USD
Net Debt/EBITDA7.43
Net Debt/FCF—
Balance Sheet
Debt/Equity0.99
Current Ratio2.01
Quick Ratio0.88
Book Value/Sh13.42 USD
Cash/Share1.74 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateJun 5, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.51.55M
Float31.59M
Insiders30.50%
Institutions14.82%
Short Interest
Short Ratio0.1d
Short % Float0.00%
Short % Out.0.00%
Shares Short1.68K
Short (prev mo.)3.98K
Technical
SMA 509.484 (-30.1%)
SMA 20011.13 (-40.4%)
Beta—
S&P 52W Chg13.09%
Avg Vol (30d)22.48K
Avg Vol (10d)30.77K
Technical Indicators
RSI (14)27.0
MACD-0.9982
MACD Signal-1.0065
MACD Hist.+0.0083
BB Upper9.024 USD
BB Middle7.464 USD
BB Lower5.903 USD
BB Width41.81%
ATR (14)0.4302 USD
Vol Ratio (20d)0.62x

About Vireo Growth (CNSX: VREO)

›

Vireo Growth (CNSX: VREO) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 520 employees.

The shares were at 9.450 CAD on 13 November 2026, down 66.8% over 52 weeks. Its 52-week range is 8.500 CAD to 31.50 CAD: the price is 70.0% below the high and 11.2% above the low.

Its market capitalisation is 552.49M CAD.

Vireo Growth reports return on equity of -22.2% and an operating margin of 6.6%.

Its debt exceeds its cash by 429.50M USD, a debt-to-equity ratio of 0.99. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 16 March 2027.

Compare VREO with MRK and TAK →More Canada stocks: Canadian Stock Screener →